Your browser doesn't support javascript.
loading
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita; Zhao, Fengmin; Lee, Sandra; Liao, Xiaoyun; Rodig, Scott; Li, Jingjing; Wu, Xinqi; Butterfield, Lisa H; Piesche, Matthias; Manos, Michael P; Eastman, Lauren M; Dranoff, Glenn; Freeman, Gordon J; Hodi, F Stephen.
Afiliação
  • Zhou J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Mahoney KM; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Giobbie-Hurder A; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Zhao F; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Lee S; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Liao X; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Rodig S; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Li J; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wu X; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Butterfield LH; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Piesche M; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Manos MP; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Eastman LM; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Dranoff G; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Freeman GJ; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hodi FS; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Cancer Immunol Res ; 5(6): 480-492, 2017 06.
Article em En | MEDLINE | ID: mdl-28522460
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Antígeno B7-H1 / Antígeno CTLA-4 / Antineoplásicos Imunológicos / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Antígeno B7-H1 / Antígeno CTLA-4 / Antineoplásicos Imunológicos / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article